Press Release
 |
| 23 April 2009 |
| Elan and Transition Therapeutics Receive Key Patent for Alzheimer's Disease Treatment with ELND005 |
“The issuance of this patent is an important milestone in the
development of ELND005, a unique oral compound with a favourable safety
profile that crosses the blood-brain barrier and targets the
disaggregation of amyloid beta in the brain,” said Dr. In 2006, Elan and Transition entered into an exclusive, worldwide collaboration agreement for the joint development and commercialization of ELND005 for the treatment of Alzheimer’s disease and other indications. About ELND005 (AZD-103)
ELND005 is an orally-administered therapeutic agent that has received
fast track designation from the ELND005 is currently in a Phase 2 clinical study. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in approximately 340 patients with mild to moderate Alzheimer’s disease. About Alzheimer’s Disease
Alzheimer’s disease, a leading cause of dementia, is a progressive brain
disorder that gradually destroys a person's memory and ability to learn,
reason, make judgments, communicate and carry out daily activities.
Alzheimer’s disease may result from the build-up of toxic beta-amyloid
peptides in the brain. As Alzheimer’s disease progresses, individuals
may also experience changes in personality and behavior, such as
anxiety, suspiciousness or agitation, as well as delusions or
hallucinations. It is currently estimated that more than 5 million
Americans have Alzheimer’s disease and more than 24 million people
worldwide over the age of 60 have some form of dementia (Source:
Alzheimer’s Association and Alzheimer’s About Elan
About Transition
Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead products
include ELND005 (AZD-103) for the treatment of Alzheimer's disease and
TT-223 for the treatment of diabetes. Transition has an emerging
pipeline of preclinical drug candidates acquired externally and
developed internally using its proprietary drug discovery engine.
Transition's shares are listed on the NASDAQ under the symbol "TTHI" and
the Safe Harbor / Forward-Looking Statements
This press release contains forward-looking statements regarding the
development of scyllo-inositol (ELND005) under the collaboration
agreement between Elan and Transition. These statements are based on
Elan's and Transition's current beliefs and expectations. ELND005 may
not be successfully developed or commercialized under the collaboration
agreement. Factors which could cause actual results to differ materially
from Elan's and Transition's current expectations include the risks that
clinical development of ELND005 fails due to safety or efficacy issues,
the results from Phase 1 clinical trials and preclinical testing of
ELND005 are not predictive of results to be obtained in Phase 2 or later
clinical trials, the patent issued with respect to ELND005 may not
provide substantial protection or commercial benefit, the development
and commercialization of competitive therapies, the collaboration
agreement is terminated early or Elan and Transition encounter other
unexpected delays or hurdles. Drug development and commercialization
involves a high degree of risk. For more detailed information on the
risks and uncertainties associated with Elan and Transition's drug
development and other activities, see the periodic and current reports
that Elan has filed with the
Source:
Elan:
|
 |
 RSS Feeds |  E-mail Alerts |  Contact IR |